Treatment with Dupixent (dupilumab) — approved in the U.S. for five inflammatory conditions, to date — once again resulted in significantly fewer exacerbations, or periods of sudden symptom worsening, among people with moderate to severe chronic obstructive pulmonary disease (COPD) in the second of two similarly designed Phase 3…

In the U.S., many people with diagnosed or probable chronic obstructive pulmonary disease (COPD) at higher risk of disease exacerbations are not receiving recommended care, a new study found. “This analysis reveals the gaps and opportunities for improvement in the identification and management of patients with COPD in the…

Prompt treatment with Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) after a moderate or severe chronic obstructive pulmonary disease (COPD) exacerbation can lower the risk of a future worsening episodes. That’s according to data by AstraZeneca, which markets Breztri Aerosphere, in the late-breaking abstract, “Exacerbations and Real-world Outcomes…

Ensifentrine, Verona Pharma’s experimental inhalation therapy, safely and effectively improves lung function and reduces the rate and risk of exacerbations, or episodes of disease worsening, in people with moderate to severe chronic obstructive pulmonary disease (COPD). That is according to top-line, six-month data from the Phase 3 ENHANCE-2…

A Phase 2 trial designed to test a self-administered inhaled formulation of nitric oxide (NO) for adults with chronic obstructive pulmonary disease (COPD), or bronchiectasis, is recruiting eligible patients. The formulation, called RESP301, is a liquid solution that, once inhaled through a nebulizer, releases NO into the lungs. RESP301 was…

An international team of researchers has published a new framework, dubbed the Rome proposal, for defining and classifying exacerbations of chronic obstructive pulmonary disease (COPD). “The ‘Rome Proposal’ represents an important milestone for better understanding and treating a very important and troubling component of COPD progression and, the prospect…

One hundred patients have been randomly assigned in Nuvaira’s pivotal AIRFLOW-3 clinical trial that will investigate the efficacy and safety of targeted lung denervation (TLD) to reduce exacerbations, or episodes of symptom worsening, of chronic obstructive pulmonary disease (COPD) in patients on optimal medical care. Because of the…

Hospitalizations for chronic obstructive pulmonary disease (COPD) dropped by half after the implementation of public health measures to curb the spread of COVID-19 infections, according to a U.S. study. This reduction in COPD hospital admissions was 36% greater than “the declines seen in other serious medical conditions, including…

Note: This story was updated May 21, 2021, as an earlier version of this article misidentified Renu Jain, PhD, scientific director of medical affairs at GlaxoSmithKline.  People with chronic obstructive pulmonary disease (COPD) who do not experience exacerbations, or flare-ups, within the previous 12 months are still at risk…

Lung function and quality of life remained stable over three years of follow-up among people with chronic obstructive pulmonary disease (COPD) treated with targeted lung denervation (TLD) — a new therapy developed by Nuvaira — according to the results of a clinical trial. That trial, called AIRFLOW-1 (…